Bayer Aktiengesellschaft

Takeda Gmbh

Nycomed Gmbh

Byk Gulden Lomberg Chemische Fabrik Gmbh

Altana Pharma Ag

Astrazeneca Ab

Armin Hatzelmann

Siegfried Raddatz

Michael Matzke

Romanis Fruchtmann

Klaus-Helmut Mohrs

Degenhard Marx

Reiner Muller-Peddinghaus

Christof Zitt

Hans-Peter Kley

Beate Schmidt

Geert Jan Sterk

Dieter Flockerzi

Christian Kohlsdorfer

Pia Theisen-Popp

Andrea Wohlsen

Anke Heuser

Hermann Tenor

Ulrich Kautz

Rolf-Peter Hummel

Christian Scheufler

Martin Feth

Clemens Braun

Deborah Ockert

Steffen Weinbrenner

Thomas Maier

Gerhard Grundler

Martin Viertelhaus

Wiro M P B Menge

Christian Hesslinger

Stefan Fischer

Andreas Pahl

Johannes A M Christiaans

Raimund Külzer

Ragna Hussong

Ewald Benediktus

Anna Rosiak

Jens Christoffers

Imre Schlemminger

Josef Stadlwieser

Christian Schudt

Torsten Dunkern

Jürgen Volz

Rolf Beume

Friedrich Grimminger

Anna Christoffers

Hossein Ardeschir Ghofrani

Juergen Volz

Thomas Stengel

Serge Adnot

Reiner M uller-Peddinghaus

Manuela Hessmann

Alexander Mann

Harald Ohmer

Saadia Eddahibi

Maria Vittoria Chiesa

Jens Prof Dr Christoffers

Martin P Feth

Johannes Barsig

Wiro MPB Menge

Thorsten Dunkern

Herrmann Tenor

Tobias Kanacher

Hans Christof Holst

The compounds of Formula (I), are novel effective inhibitors of the type 4 phosphodiesterase.

Pyrazolone-derivatives and their use as PDE-4 inhibitors

The compound 1-(2-{4-[3-(3,4-dimethoxyphenyl)-4,4-dimethyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl]piperidin-1-yl}-2-oxoethyl)pyrrolidine-2,5-dione is a novel effective inhibitor of the type 4 phosphodiesterase useful in the treatment of psoriasis or atopic dermatitis.

Pyrazolone derivatives as PDE4 inhibitors

The compounds of Formula (1), in which A, R1, R2, R3 and R5 have the meanings as given in the description, are novel effective inhibitors of type 4 and 5 phosphodiesterase.

3,4,4a,10b-Tetrahydro-1H-thiopyrano-[44,3-c] isoquinoline derivatives

The compound 1-(2-{4-[3-(3,4-dimethoxyphenyl)-4,4-dimethyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl]piperidin-1-yl}-2-oxoethyl)pyrrolidine-2,5-dione is a novel effective inhibitor of the type 4 phosphodiesterase.

The invention relates to the use of Roflumilast, Roflumilast N-Oxide or a pharmaceutically acceptable salt of either for the treatment of pulmonary hypertension. The invention additionally relates to the use of Roflumilast, Roflumilast N-oxide or a pharmaceutically acceptable salt of either in combination with a PDE5 inhibitor or a pharmaceutically acceptable salt thereof for the treatment of pulmonary hypertension.

Roflumilast for the treatment of pulmonary hypertension

The compounds of a certain formula 1, in which R1, R7, R8, R9 and n have the meanings as given in the description, are novel effective inhibitors of the type 4 phosphodiesterase.

The compounds of formula I in which R1, R2 and R3 have the meanings as given in the description, are novel effective PDE4 inhibitors.

3-oxa-10-aza-phenanthrenes

The compounds of formula I in which A, R1, R2 and R3 have the meanings as given in the description, are novel effective PDE4 inhibitors.

3-thia-10-aza-phenanthrene derivatives

3,4-Dihydroisoquinoline and isoquinoline compounds of formula I, in which Ar represents a phenyl raidcal of the formulae IIa, IIb or IIc are novel effective PDE7 inhibitors.

(Dihydro) isoquinoline derivatives as phosphodiesterase inhibitors

Compounds 8,9-diethoxy-2-methyl-6-&lsqb;4(p-toluenesulfonamide) phenyl&rsqb;-1,2,3,4,4a,10b-hexahydrobenzo&lsqb;c&rsqb;&lsqb;1,6&rsqb;naphthyridine and 9-ethoxy-8-methoxy-2-methyl-6-&lsqb;4-(p-toluenesulfonamido)phenyl&rsqb;-1,2,3,4,4a,10b-hexahydrobenzo&lsqb;c&rsqb;&lsqb;1,6&rsqb;naphthyridine and medicament compositions based thereon are useful for treating airway disorders, high blood pressure disorders and concomitant disorders connected therewith.

Benzonaphthyridine

Substituted quinol-2-yl-methoxy-phenylacetic acid derivatives are prepared by reacting correspondingly substituted phenols with quinolylmethyl halides or by reacting unsubstituted phenols with quinolylmethyl halides and subsequent alkylation. The substituted quinol-2-yl-methoxy-phenylacetic acid derivatives may be employed as active substances in medicaments.

Substituted quinol-2-yl-methoxy-phenylacetic acid derivatives

The novel quinolin-2-yl-methoxybenzylhydroxyureas can be prepared by reaction of appropriate ketones with hydroxylamine and reduction of the ketoximes and subsequent reaction with isocyanates. The new substances can be employed as active substances in medicaments.

Quinolin-2-yl-methoxybenzylhydroxyureas

Quinolylmethoxyphenyl-acetamides of the formula: ##STR1## in which A, B, D, E, G, L and M are hydrogen, hydroxyl, halogen, cyano, carboxyl, nitro, trifluoromethyl, trifluoromethoxy, alkyl, alkoxy or optionally substituted aryl;

Quinolylmethoxyphenyl-acetamides

The title compounds are prepared either by reacting the corresponding halogenomethylquinolines with substituted phenols, optionally subsequently alkylating these or hydrolysing esters to acids, or by reacting phenyl-substituted quinolinecarboxylic acid derivatives with sulphonamides. The new phenyl-substituted quinolines are utilizable as active substances in medicaments, in particular as lipoxygenase inhibitors.

2-substituted quinolines, and their use in medicaments

Growing community of inventors

Constance, Germany

Armin Hatzelmann